Alpha 2.0
Login Register
» Articles » PMID: 27300660

The Difficulty of Comparing Drug Prices Between Countries

Overview
Journal Lancet Oncol
Specialty Oncology
Date 2016 Jun 15
PMID 27300660
Citations 4
Authors
Maggie De Block
Affiliations
Soon will be listed here.
Citing Articles

Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions.

Tranvag E, Haaland O, Robberstad B, Norheim O JAMA Netw Open. 2022; 5(6):e2219503.

PMID: 35767256 PMC: 9244608. DOI: 10.1001/jamanetworkopen.2022.19503.

Determinants of drug prices: a systematic review of comparison studies.

Janssen Daalen J, den Ambtman A, Houdenhoven M, van den Bemt B BMJ Open. 2021; 11(7):e046917.

PMID: 34266841 PMC: 8287090. DOI: 10.1136/bmjopen-2020-046917.

Patients' access to drugs with rebates in Switzerland - Empirical analysis and policy implications for drug pricing in Europe.

Carl D, Vokinger K Lancet Reg Health Eur. 2021; 3:100050.

PMID: 33899044 PMC: 7610666. DOI: 10.1016/j.lanepe.2021.100050.

How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?.

Harkins R, Flowers C Leuk Lymphoma. 2020; 61(14):3283-3286.

PMID: 33143518 PMC: 7959248. DOI: 10.1080/10428194.2020.1837798.